Elevated Capital Advisors’s AstraZeneca AZN Stock Holding History

Elevated Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.39K	Hold	39	–	–	﹤0.01%	523
2026 Q1	$7.69K	Hold	39	–	–	﹤0.01%	494
2025 Q4	$7.17K	Buy	+39	New	+$6.84K	﹤0.01%	486

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Elevated Capital Advisors's AZN Position: Q2 2026 in Review

Elevated Capital Advisors held its AstraZeneca (AZN) position steady in Q2 2026 at 39 shares worth $7.39K. The position accounts for ﹤0.01% of the portfolio, ranked #523.

Elevated Capital Advisors first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.69K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Elevated Capital Advisors held 39 shares of AstraZeneca worth $7.39K as of Q2 2026.
Elevated Capital Advisors left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up ﹤0.01% of Elevated Capital Advisors's portfolio in Q2 2026, its #523 holding.
Elevated Capital Advisors first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
Elevated Capital Advisors's AstraZeneca position peaked at $7.69K in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Elevated Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.